# Alio

> Alio is a Broomfield, Colorado medical technology company that builds a non-invasive, continuous remote patient monitoring platform for people with chronic conditions. Its flagship SmartPatch - the world's first non-invasive potassium monitor - is worn over a patient's vascular access site and tracks metrics such as potassium, hemoglobin, hematocrit, heart rate, skin temperature and auscultation sounds, sending clinician-ready data to care teams via a bedside hub, cloud and portal. Founded in 2012 (originally as Graftworx) by David Kuraguntla and Samit Gupta, Alio focuses first on end-stage kidney disease and dialysis patients, aiming to replace infrequent blood draws with continuous data and cut avoidable hospitalizations.

- **Founded:** 2012
- **Headquarters:** Broomfield, Colorado, United States
- **Founders:** David Kuraguntla (Co-Founder & CEO), Samit Gupta (Co-Founder & CTO)
- **Team size:** ~47 employees
- **Products:** Alio SmartPatch, Alio Bedside Hub, Alio Medical Cloud, Clinician Portal
- **Notable:** Built the world's first non-invasive potassium monitor (2023)., Received FDA 510(k) clearance for its remote patient monitoring platform (April 2022) for skin temperature, auscultation sound and heart rate., Expanded FDA-cleared metrics to include hematocrit, hemoglobin and potassium (2023).

## Products & services

- **Alio SmartPatch** — A non-invasive wearable sensor worn over the arteriovenous fistula or an upper-extremity artery that continuously captures potassium, hemoglobin, hematocrit, heart rate, skin temperature and auscultation sounds. The world's first non-invasive potassium monitor.
- **Alio Bedside Hub** — A device that collects data from the SmartPatch and securely uploads it to the Alio Medical Cloud.
- **Alio Medical Cloud** — Cloud infrastructure that stores raw patch data and processes it with proprietary algorithms into clinically actionable metrics.
- **Clinician Portal** — A care-team-facing portal that presents processed metrics and alerts so clinicians can monitor patients remotely and intervene early.

## Achievements

- Built the world's first non-invasive potassium monitor (2023).
- Received FDA 510(k) clearance for its remote patient monitoring platform (April 2022) for skin temperature, auscultation sound and heart rate.
- Expanded FDA-cleared metrics to include hematocrit, hemoglobin and potassium (2023).
- Designed the SmartPatch to work across all skin tones.
- Raised $18M Series C, bringing total funding past $61M.
- Recognized as a top nephrology and urology products company (2022) and won an ASDIN prize.

## Latest updates

- **2024-09** — Launched the Calibration and Validation (CAVA) study to expand the Alio platform's FDA clearance beyond the vascular access site for use in a broader range of patients.
- **2023-03** — Announced the SmartPatch as the world's first non-invasive potassium monitor, adding potassium, hemoglobin and hematocrit to its cleared metrics.
- **2022-12** — Raised $18M in the first close of a Series C round led by the Widjaja Family Investment Office.
- **2022-04** — Received FDA 510(k) clearance for its remote patient monitoring platform.

## Links

- Website: https://alio.ai
- LinkedIn: https://www.linkedin.com/company/aliomedical
- Twitter/X: https://twitter.com/WeAreAlio

---

Profile page: https://yespress.io/alio
Published by YesPress — https://yespress.io
Last updated: 2026-07-14